DaVita launches venture group
DaVita has launched a venture group as part of its efforts to improve the health care of patients with kidney disease, the company announced.
The group, known as DaVita Venture Group (DVG), will seek partnerships and venture investment opportunities with a focus on digital health, pharmaceuticals, medical devices and care delivery models, according to a company press release.
“DaVita Venture Group aims to find new solutions for our patients that go beyond dialysis," Steve Phillips, vice president of innovation for DVG, said in the release. “We’re excited to fund select venture capital investments in early stage companies, which will have the potential to drive innovation over time.”
The release indicated that ultimate goals of the DVG are to expand access to patient-centered care, improve clinical outcomes and reduce costs.
According to Javier Rodriguez, CEO of DaVita, the company believes developing innovative solutions is the most effective way to advance and improve patient care.
“We want to transform kidney health – from chronic kidney disease to transplant – and we're putting financial and strategic resources into these solutions,” he said. “We believe we can be the partner of choice for entrepreneurs who want to bring best in class technology and innovations to market.”
Mahesh Krishnan, group vice president of research and development for DVG, also weighed in on the group’s launch.
“This is an exciting time in health care as entrepreneurs, researchers and industry leaders envision solutions that could change care delivery for the better,” he said. “We believe we can help drive that change, and that DaVita Venture Group is a great incubator to help advance these solutions to market.”